- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03046953
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma (AVAIL-T)
A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
The AVAIL-T trial is designed to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refratory to or has relapsed following initial treatment. Up to 36 people will be taking part in the AVAIL-T trial at hospitals across the United Kingdom. All patients on the trial will be recruited over 2 years and recieve up to 8 cycles of avelumab treatment. Avelumab is an anti-PD-L1 antibody that will be given as an infusion once every 2 weeks in cycles lasting 28 days. The trial will be looking at the response to aveulumab, by mesuring the change in the tumour size using CT scans, and seeing how long that response is maintained. The trial will also look at toxicity, overall survival, and progression free survival.
In addition we will analyse blood samples and samples of the cancer to understand better how the cancer behaves. This may guide the investigators in developing better treatments in the future.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- University College London Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged ≥ 16 years
- Life expectancy > 12 weeks
- ECOG performance status ≤ 2
- Relapsed or refractory* peripheral T-cell lymphoma including the following histologies: peripheral T-cell lymphoma not otherwise specified (PTCL NOS) , angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy associated T-cell lymphoma (EATL), extranodal NK/T- cell lymphoma (ENKL), transformed mycosis fungoides (LCT MF), hepatosplenic T-cell lymphoma (HSTCL) * For all relapsed patients, relapse must be confirmed by tissue biopsy (or bone marrow trephine if no other tissue available). For refractory patients, a biopsy must have been obtained within the last 3 months
- Failed at least 1 prior therapy (but no upper limit of prior regimens)
Adequate haematological function defined by at registration:
- absolute neutrophil count (ANC) ≥ 1.0 × 109/L, (unsupported)
- platelet count ≥ 75 × 109/L, (unsupported)
- haemoglobin ≥ 9 g/dL (may have been transfused)
Adequate hepatic function defined by:
- total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range
- AST or ALT levels ≤ 2.5 × ULN for all patients or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver)
- Adequate renal function defined by an estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
- CT measurable disease with at least 1 lesion having short axis > 1.5cm or splenomegaly > 14cm in cranio-caudal length attributable to relapsed/non responding lymphoma
- Negative serum pregnancy test at screening for women of childbearing potential.
- Highly effective contraception for both male and female patients if the risk of conception exists. (Note: women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1 % per year. Highly effective contraception is required from consent, throughout and for at least 60 days after avelumab treatment.
- Ability to give informed consent
Exclusion Criteria:
Patients are not eligible for the trial if they fulfill any of the following exclusion criteria:
- All patients with active CNS involvement of lymphoma
- Prior organ transplantation, including allogeneic stem cell transplantation
Significant acute or chronic infections including, among others:
- Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS),
- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
Current use of immunosuppressive medication, EXCEPT for the following:
- intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); Systemic corticosteroids at a maximum dose of ≤ 1 mg/kg of prednisone or equivalent during screening (to be stopped by day 1 of trial treatment); Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Active autoimmune disease that might deteriorat e when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3)
- Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy Grade ≤ 2 or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable are acceptable
- Pregnancy or lactation
- Known alcohol or drug abuse
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to registration), myocardial infarction (< 6 months prior to registration), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
- Active infection requiring systemic therapy
- Major surgery within 4 weeks of trial entry
- Patients and partners of childbearing potential not willing to use two methods of effective contraception during and for 60 days after therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Avleumab
Avelumab 10mg/kg by IV infusion once every 2 weeks.
A maximum of 8 cycles, each cycle is 28 days.
|
anti-PDL1 antibody
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall resposne rate during the first 8 cycles of treatment
Time Frame: 8 cycles (224 days)
|
Best overall response rate (CR + PR) during the first 8 cycles of treatment will be assessed using contrast-enhanced CT scans of the neck, chest, abdomen and pelvis, using the Revised Response Criteria for Malignant Lymphoma
|
8 cycles (224 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity- Number of Patients
Time Frame: During treatment of 8 cycles (224 days)
|
Toxicity assessed using CTCAE v4.0 will be defined as the number of patients who experience one or more grade 3 or 4 adverse event or serious adverse event of any grade
|
During treatment of 8 cycles (224 days)
|
Toxicity- Proportion of Patients
Time Frame: During treatment of 8 cycles (224 days)
|
Toxicity assessed using CTCAE v4.0 will be defined as the proportion of patients who experience one or more grade 3 or 4 adverse event or serious adverse event of any grade
|
During treatment of 8 cycles (224 days)
|
Maximum percentage change in sum of product of diameters
Time Frame: During trial treatment of 8 cycles (224 days)
|
Maximum percentage change in the sum of the product of diameters (SPD) of target tumour masses assessed by contrast-enhanced CT scans of the neck, chest, abdomen and pelvis, using the Revised Response Criteria for Malignant Lymphoma
|
During trial treatment of 8 cycles (224 days)
|
Duration of Response
Time Frame: 2 years
|
Duration of response is defined as the time from first documented response until relapse/progression, as determined by the Revised Response Criteria, or death.
Patients who are relapse/progression free and alive will be censored at date last seen.
|
2 years
|
Progression free survival
Time Frame: 2 years
|
Progression free survival is defined as the time from date of registration to the date of disease progression or date of death from any cause.
Patients not reaching progression or death at the time of analysis will be censored at the last date they were known to be alive and progression free.
|
2 years
|
Overall survival
Time Frame: 2 years
|
Overall survival time is defined as the time from date of registration to the date of death from any cause.
Patients discontinuing the study, lost to follow-up or still alive at the end of the study will be censored at the date of last follow-up.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Simon Wagner, MD, Univeristy of Leicester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG_16-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on T-Cell Lymphoma Relapsed
-
AstraZenecaCompletedRelapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins LymphomaItaly, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
Fondazione Italiana Linfomi - ETSTerminatedT-Cell Lymphoma Relapsed | T-Cell Lymphoma RefractoryItaly
-
National Cancer Institute (NCI)Active, not recruitingCutaneous T-Cell Lymphoma | Peripheral T-Cell Lymphoma | Mature T-cell Malignancies | Relapsed/ Refractory T-cell MalignanciesUnited States
-
Kyowa Kirin, Inc.Active, not recruitingCutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, RelapsedUnited States, United Kingdom, Spain, France, Italy
-
Dana-Farber Cancer InstituteLeadiant Biosciences, Inc.TerminatedT-Cell Lymphoma | Relapsed T-Cell Lymphoma | Refractory T-Cell LymphomaUnited States
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
-
The Lymphoma Academic Research OrganisationCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaFrance, Belgium
-
Millennium Pharmaceuticals, Inc.CompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaUnited States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
-
Fondazione Italiana Linfomi ONLUSActive, not recruitingRelapsed T-Cell Lymphoma | Refractory T-Cell LymphomaItaly
Clinical Trials on Avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada
-
McGill University Health Centre/Research Institute...RecruitingGastric Adenocarcinoma | Esophageal AdenocarcinomaCanada
-
PfizerNot yet recruitingUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada